Distribuzione geografica
Continente #
NA - Nord America 5573
EU - Europa 5292
AS - Asia 2249
AF - Africa 64
OC - Oceania 23
SA - Sud America 16
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13221
Nazione #
US - Stati Uniti d'America 5469
CN - Cina 1454
DE - Germania 819
IT - Italia 732
IE - Irlanda 681
SE - Svezia 600
UA - Ucraina 561
FR - Francia 516
KR - Corea 460
FI - Finlandia 419
AT - Austria 233
DK - Danimarca 176
GB - Regno Unito 172
PL - Polonia 161
VN - Vietnam 107
CA - Canada 99
JP - Giappone 85
BE - Belgio 62
SN - Senegal 59
IN - India 43
ES - Italia 23
NL - Olanda 23
GR - Grecia 22
AU - Australia 21
RU - Federazione Russa 19
TW - Taiwan 17
CH - Svizzera 16
HK - Hong Kong 16
BY - Bielorussia 13
IR - Iran 11
CZ - Repubblica Ceca 10
RO - Romania 10
TR - Turchia 9
BR - Brasile 8
SA - Arabia Saudita 8
PH - Filippine 7
PT - Portogallo 7
PK - Pakistan 6
CL - Cile 5
MX - Messico 5
NO - Norvegia 5
TH - Thailandia 5
UZ - Uzbekistan 5
EU - Europa 4
MO - Macao, regione amministrativa speciale della Cina 4
HU - Ungheria 3
MU - Mauritius 3
MY - Malesia 3
RS - Serbia 3
AR - Argentina 2
IQ - Iraq 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
SG - Singapore 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
EG - Egitto 1
ID - Indonesia 1
IL - Israele 1
LB - Libano 1
LT - Lituania 1
PE - Perù 1
QA - Qatar 1
ZA - Sudafrica 1
Totale 13221
Città #
Beijing 999
Chandler 817
Dublin 681
Ann Arbor 413
Villeurbanne 398
Jacksonville 356
Houston 307
Princeton 300
Torino 257
Medford 252
Fairfield 243
Vienna 199
Wilmington 192
Dearborn 180
Nyköping 170
Warsaw 158
Ashburn 133
Woodbridge 117
Redwood City 110
Boston 87
Cambridge 79
San Mateo 78
Seattle 72
Dong Ket 71
Fremont 70
Pisa 70
Milan 64
Boardman 63
Brussels 58
Shanghai 51
Centro 45
Toronto 45
Guangzhou 43
Verona 43
Nanjing 41
Falls Church 31
Norwalk 30
Philadelphia 30
Hefei 25
Chengdu 23
Lachine 23
Tokyo 21
Mountain View 19
New York 19
Kunming 18
Düsseldorf 17
Hangzhou 16
Jinan 16
Turin 16
Zhengzhou 16
Ottawa 15
Bologna 14
Fuzhou 14
Nürnberg 13
San Diego 12
Taipei 12
Wuhan 12
Phoenix 11
Rome 11
Shenyang 11
Tianjin 11
Detroit 10
Nanchang 10
Xian 10
Grafing 9
Redmond 9
Cleveland 8
Des Moines 8
Munich 8
Barcelona 7
Central District 7
Changsha 7
Rochester 7
Changchun 6
Chicago 6
Fountain Valley 6
Kish 6
Leiden 6
Buffalo 5
Columbus 5
Genova 5
Hebei 5
Kharkiv 5
Monmouth Junction 5
New Haven 5
Paris 5
San Jose 5
Silver Spring 5
Ancona 4
Bangkok 4
Baotou 4
Bar Harbor 4
Chongqing 4
Dallas 4
Delhi 4
Geneve 4
Saint Petersburg 4
Somerville 4
São Paulo 4
Tampa 4
Totale 7946
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 563
PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. 425
Core binding factor acute myeloid leukaemia and c-KIT mutations 349
PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. 300
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. 289
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. 244
p130Cas mediates the transforming properties of the anaplastic lymphoma kinase 234
The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation 215
The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. 210
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors 186
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling 182
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. 164
STAT3-mediated activation of microRNA cluster 17~92 promotes proliferation and survival of ALK positive anaplastic large cell lymphoma. 163
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma 160
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 160
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 148
The influence of tissue ischemia time on RNA integrity and patient-derived xenografts (PDX) engraftment rate in a non-small cell lung cancer (NSCLC) Biobank 147
Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials 138
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas 136
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma 128
The genetics of nodal marginal zone lymphoma 117
Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma 112
Core binding factor acute myeloid leukemia and c-kit mutations 107
Anaplastic lymphoma kinase in human cancer 103
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 101
PDX-MI: Minimal information for patient-derived tumor xenograft models 100
Epidermal Growth Factor Receptor Gene in Primary Tumor and Metastatic Sites from Non-small Cell Lung Cancer. J Thorac Oncol. 2009 Apr 29 99
The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL 97
Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas 96
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 96
The heterogeneous landscape of ALK negative ALCL 95
Analysis of the activating Kras mutations in advanced colorectal tumors: a three-year diagnostic experience 90
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 88
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 83
Genomic and functional approaches as powerful tools to stratify human T-cell lymphoproliferative disorders and to identify relevant tumorigenic culprits 82
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination 80
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 80
CD30 expression in anaplastic large cell lymphomas is dependent on ALK tyrosine kinase activity via Stat3 phosphorylation and JunB upregulation 80
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma 79
MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma 77
Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death 75
Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination 75
Cell of origin markers identify different prognostic subgroups of lung adenocarcinoma 75
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 72
Molecular anatomy of peripheral T cell lymphomas 71
Ablation of oncogenic ALK is a viable therapeutic approach fAblation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas 70
Anaplastic large-cell lymphoma 70
The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM1), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells 69
Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation 68
Unveiling the pathogenetic role of Stat3 in human lymphoma 68
Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. 68
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes 67
NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells 66
Association of low P27 with loss of hormone receptors in small (T1a/b) breast cancers 66
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression. 66
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target 64
NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. 64
Detection of immunoglobulin kappa light chain rearrangements by polymerase chain reaction. An improved method for detecting clonal B-cell lymphoproliferative disorders. 62
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 62
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase 62
Induction of germinal centers by MMTV encoded superantigen on B cells. 61
The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration 61
A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation 61
Identification of genomic and proteomic signatures in lymphomas by inducible shRNA 61
Stem cells based therapy in high grade glioma: why the intraventricular route should be preferred? 61
Development of a consensus IgH quantitative assay for the detection of minimal residual disease in Chronic Lymphocytic Leukemia using 3’-minor groove binder probes. 61
Anaplastic lymphoma kinase: an oncogene for tumor vaccination 61
Anaplastic lymphoma Kinase: molecular mechanisms of lymphoid transformation 60
Identification of molecular classifiers and key signalling networks in T-cell lymphoproliferative disorders through gene expression profiling meta-analyses 60
Dendritic cells transfected with DNA encoding ErbB2 rat/human chimeric plasmids are able to activate in vitro a specific T cell response in ErbB2+ cancer patients 59
Anti-Hu-associated peripheral nerve and muscle microvasculitis. 59
The usefulness of immunophenotypic and genotypic studies in the diagnosis and classification of hematopoietic and lymphoid neoplasms. An update. 58
Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. 58
Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity 57
Autoantibody-associated cross-reactive idiotype-bearing human B lymphocytes: distribution and characterization, including Ig VH gene and CD5 antigen expression 56
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. 56
Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma? 54
N- and K-ras oncogenes in plasma cell dyscrasias. 54
CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib 53
Network-based inference of tumorogenic culprits in human T-cell lymphoproliferative disorders 53
The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. 53
The anaplastic lymphoma kinase in the pathogenesis of cancer 53
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 53
Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells 52
Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells 52
The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. 51
Mutational activation of N-and K-RAS oncogenes in plasma cell dyscrasia. 51
Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas 51
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. 51
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms 51
Gene Expression Profiling Uncovers Molecular Classifiers for theRecognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms 50
Transposable elements: The enemies within 50
ALK protein tyrosine kinase, cells and methods embodying and using same 49
Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. 49
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma 49
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. 47
Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. 46
Phenotypic and functional characterization of T-BAM (CD40 ligand)+ T-cell non-Hodgkin's lymphoma. 46
Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. 46
Increase in circulating bone marrow progenitor cells after myocardial infarction 45
Totale 9922
Categoria #
all - tutte 24482
article - articoli 0
book - libri 0
conference - conferenze 2690
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27172

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201831 0000 00 00 00031
2018/20191033 51227240 34104 62162 638823996
2019/20202078 5774137210 166337 296146 194189165107
2020/20211645 18385132100 17766 18455 201167111184
2021/20222188 9291100194 87154 183110 71204381521
2022/20232672 40321144252 221717 260139 249751010
Totale 13832